Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

BI 836858 Dose Escalation in Patients With Refractory or Relapsed Acute Myeloid Leukemia and in Patients With AML in Complete Remission With High Risk to Relapse

Phase 1

Completed

Conditions: Leukemia, Myeloid, Acute

Interventions: Drug: BI 836858

First Posted Date: 2012-09-24

Last Posted Date: 2025-01-27

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 30

Registration Number: NCT01690624

Locations: 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
The Ohio State University Wexner Medical Center, Columbus, Ohio, United States

and more 2 locations

Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BI 655075 Administered Alone or With Dabigatran Etexilate

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Dabigatran
Drug: Placebo
Drug: BI 655075

First Posted Date: 2012-09-20

Last Posted Date: 2016-06-23

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 157

Registration Number: NCT01688830

Locations: 🇧🇪
1321.1.1 Boehringer Ingelheim Investigational Site, Antwerpen, Belgium

Efficacy, Pharmacokinetics, and Safety of BI 695500 in Patients With Rheumatoid Arthritis

Phase 3

Terminated

Conditions: Arthritis, Rheumatoid

Interventions: Drug: BI 695500
Drug: Rituxan®
Drug: MabThera®

First Posted Date: 2012-09-11

Last Posted Date: 2018-01-30

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 294

Registration Number: NCT01682512

Locations: 🇺🇸
Medication Management, LLC, Greensboro, North Carolina, United States
🇺🇸
Adriana Pop Moody Clinic PA, Corpus Christi, Texas, United States
🇵🇹
Centro Hospitalar do Baixo Vouga, E.P.E. Unidade de Aveiro, Aveiro, Portugal

and more 104 locations

Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of BI 113608 in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo to BI 113608 PIB bid
Drug: Placebo to BI 113608 PIB qd
Drug: BI 113608 PIB bid
Drug: BI 113608 PIB qd

First Posted Date: 2012-09-07

Last Posted Date: 2017-01-20

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 48

Registration Number: NCT01681277

Locations: 🇩🇪
Boehringer Ingelheim Investigational Site, Mannheim, Germany

Investigation of Drug-drug Interaction of Nintedanib and Ketoconazole in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Nintedanib
Drug: Ketoconazole

First Posted Date: 2012-09-06

Last Posted Date: 2014-11-27

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 34

Registration Number: NCT01679613

Locations: 🇩🇪
1199.161.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

Demonstration of Bioequivalence of Empagliflozin and Metformin Given in One Tablet Compared to the Intake of Single Tablets

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Empagliflozin + Metformin
Drug: Empagliflozin
Drug: Metformin

First Posted Date: 2012-08-27

Last Posted Date: 2015-08-31

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 36

Registration Number: NCT01672788

Locations: 🇩🇪
1276.7.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Completed

Conditions: Stroke
Atrial Fibrillation

First Posted Date: 2012-08-23

Last Posted Date: 2020-12-31

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 10471

Registration Number: NCT01671007

Locations: 🇫🇷
HOP Européen G. Pompidou, Paris, France
🇦🇹
KH der Barmherzigen Schwestern Linz, Linz, Austria
🇫🇷
CAB Cohen S, Paris, Paris, France

and more 510 locations

Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 1

Phase 4

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Placebo
Drug: tiotropium bromide

First Posted Date: 2012-08-14

Last Posted Date: 2018-10-17

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 79

Registration Number: NCT01663987

Locations: 🇺🇸
205.477.001032 Boehringer Ingelheim Investigational Site, Huntersville, North Carolina, United States
🇺🇸
205.477.001020 Boehringer Ingelheim Investigational Site, Seneca, North Carolina, United States
🇺🇸
205.477.001057 Boehringer Ingelheim Investigational Site, Tulsa, Oklahoma, United States

and more 47 locations

Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 2

Phase 4

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Placebo
Drug: tiotropium bromide

First Posted Date: 2012-08-13

Last Posted Date: 2018-10-17

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 79

Registration Number: NCT01662986

Locations: 🇺🇸
205.478.00243 Boehringer Ingelheim Investigational Site, Montgomery, Alabama, United States
🇺🇸
205.478.00240 Boehringer Ingelheim Investigational Site, Long Beach, California, United States
🇺🇸
205.478.00205 Boehringer Ingelheim Investigational Site, Lawrenceville, Georgia, United States

and more 47 locations

Volasertib in Japanese Patients With Acute Myeloid Leukemia (AML)

Phase 1

Completed

Conditions: Leukemia, Myeloid, Acute

Interventions: Drug: Volasertib

First Posted Date: 2012-08-10

Last Posted Date: 2018-07-30

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 19

Registration Number: NCT01662505

Locations: 🇯🇵
Boehringer Ingelheim Investigational Site, Yoshida-gun, Fukui, Japan

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy